Recs

11

Pros and Cons of Converting Your IRA to a Roth

By | More Articles
February 20, 2013 | Comments (8)

In this edition of our Motley Fool Conversations series, Fool personal finance expert Dayana Yochim and retirement planning analyst Dan Caplinger discuss whether converting traditional IRAs and 401(k) plans to their Roth counterparts is a smart move. Although you pay taxes up front on a conversion, the payoff is that you never have to pay taxes on your Roth assets again -- even when you take withdrawals during retirement.

Dan and Dayana go through the pros and cons of doing a Roth conversion with some specific ideas on helping you make the right decision for your own personal financial situation. In addition, Dan points out how you can take advantage of special "do-over" provisions of Roth IRA conversions in order to maximize your returns in stocks facing big binary events that will make or break their futures. Overall, whether converting makes sense depends on what your current tax rates are compared to what you expect they'll be when you retire.

Who will win the obesity drug market?
One fight involving binary events pits obesity-drug players VIVUS and Arena Pharmaceuticals. Find out which company has the best prospects by reading copies of the Fool's premium research reports on VIVUS and Arena Pharmaceuticals. Senior biotech analyst Brian Orelli gives investors the must-know information, including an in-depth look at the obesity market and reasons to buy and sell both stocks. Click now for an exclusive look at Arena and VIVUS -- complete with a full year of free updates -- today.

Jeff Fischer and team have demystified options. And they can rack up income like $1,030... $2,626... and $3,228 on a schedule you can set your watch by!
That's why we're glad to announce every single one of their closely guarded strategies is available to YOU during May and June – 100% FREE, no strings attached! Just enter your email address in the box below...

Fool contributor Dan Caplinger and personal finance expert Dayana Yochim have no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.


Read/Post Comments (8) | Recommend This Article (11)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Add your comment.

Compare Brokers

Fool Disclosure

DocumentId: 2265248, ~/Articles/ArticleHandler.aspx, 5/23/2013 4:14:25 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated 6 hours ago Sponsored by:
DOW 15,307.17 -80.41 -0.52%
S&P 500 1,655.35 -13.81 -0.83%
NASD 3,463.30 -38.82 -1.11%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

5/22/2013 4:00 PM
VVUS $13.52 Up +0.36 +2.74%
VIVUS, Inc. CAPS Rating: **
ARNA $7.92 Down -0.07 -0.88%
Arena Pharmaceutic… CAPS Rating: **

Advertisement